Company intelligence / Profile preview

FemPulse

San Francisco, California, United Statesfempulse.com ↗

Ownership: Private
Development stage: Commercial

Overview

FemPulse has completed earlier clinical studies and received FDA Investigational Device Exemption (IDE) approval in December 2024 to begin its pivotal EVANESCE II trial for overactive bladder in women. The device offers a minimally invasive alternative to pharmaceutical and surgical treatments by providing continuous neuromodulation via a vaginal ring. The system has also advanced to the final stage of the EU Medical Device Regulation process for commercial clearance

Therapeutic areas: Women's Health
Modalities: DeviceBioelectronic medicine
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Genio system

Commercial

Indications: Moderate to severe Obstructive Sleep Apnea

Partnerships

None publicly disclosed as of June 2025.

Beyond the preview

Go deeper on FemPulse.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FemPulse.

Explore the full profile